Stock Update: Bristol-Myers Squibb Company (NYSE:BMY) – Bristol-Myers Squibb Receives U.S. FDA Breakthrough Therapy Designation for All-Oral Daclatasvir Dual Investigational Regimen for Chronic Hepatitis C

[at noodls] – FDA grants Designation request for investigational daclatasvir (DCV) and asunaprevir (ASV) combination therapy for treatment of genotype 1b chronic hepatitis C (HCV) infection Marks second Breakthrough . . . → Read More: Stock Update: Bristol-Myers Squibb Company (NYSE:BMY) – Bristol-Myers Squibb Receives U.S. FDA Breakthrough Therapy Designation for All-Oral Daclatasvir Dual Investigational Regimen for Chronic Hepatitis C Similar Articles: Company Update – Gilead Sciences Inc. (NASDAQ:GILD) – Mounting optimism for hepatitis C drug boosts Gilead to lead S&P 500 Gilead Sciences Inc. (NASDAQ:GILD) – Gilead to seek okay for combo hepatitis C pill in Q1 AbbVie Inc. (NYSE:ABBV) ~ AbbVie’s hepatitis C treatment helps 96 pct of patients in trial